Indications
Nezglyal is indicated for the treatment of male ALD patients aged 2 years and older with brain lesions to delay progression of cerebral adrenoleukodystrophy (cALD).
Composition
- Active substance
- leriglitazone hydrochloride
- International name (INN)
- leriglitazone
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Nezglyal
- Active substance
- leriglitazone hydrochloride
- ATC code
- A16AX23
- Therapeutic area
- Adrenoleukodystrophy
- Marketing authorisation holder
- Minoryx Therapeutics S.L.